ClinicalTrials.gg
CompletedNCT02780323Updated Feb 5, 2020

Study to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Patients With Rheumatoid Arthritis

A Phase 4 interventional study of CELBESTA® and CELEBREX® in Rheumatoid Arthritis, sponsored by Dong-A ST Co., Ltd.. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Dong-A ST Co., Ltd. · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Nov 2015, registered May 2016).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
119
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of — 10 open to participants now, 16 under way, 2 of them phase 3. Arthritis, Rheumatoid · Korea, Republic of.

Enrollment
108th of 155
119 · median 300
Started
2015
with 13 others
Phase 4
20 of 188
none open now
Registered
129th of 188
by date

Among the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of, this one is the 108th largest by enrollment of the 155 interventional ones that give a count, is one of 14 that started in 2015, is one of 20 in phase 4, and was the 129th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

10 of the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This Phase IV clinical study is to Compare the Efficacy and Safety of CELBESTA® and CELEBREX® in Rheumatoid Arthritis Patients

Read the detailed description

Thisi is a multi-center, double-blind, active-controlled, randomized, parallel-group clinical trial to compare the efficacy and safety of CELBESTA® and CELEBREX® in patients with rheumatoid arthritis. The subject will receive two tablets twice daily for 6 weeks.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Celecoxib
  • CELBESTA
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Anyone over the age of 19
  • Subjects who are diagnosed as established rheumatoid arthritis at screening visit and before
  • Pain greater than 40/100mm-VAS(Visual Analgue Scale) after
  • Patients who are taking oral without dosage change (within a range of prednisolone 10mg a day) at least 4weeks and more than 1 DMARDs at least 3 months from screening test
  • Patients willing and able to provide signed after the nature of the study has been explained

Exclusion criteria

Exclusion Criteria:

  • History of angina pectoris or congestive heart failure at rest or minimum activity
  • History of myocardial infarction or artherosclerosis
  • Patients who had a coronary angioplaty or coronary artery bypass graft within 1 year
  • History of stroke, or hepatitis within 2 years
  • Patients who have uncontrolled hypertension at screening
  • Patients who take the medicines that might effect the test results by study investigators or might cause a excessive risk to the patients

    • Intra-articular injection within 4 weeks from screening
    • biological DMARDs such as infliximab, adlimumab, entanercept, anakinara or abatacept wihin 6 months from randomization
    • biological DMARDs such as rituximab within 1 year from randomization
  • History of a malignant tumor (except for the patients whose tumor was removed and there's no recurrence within 5 years)
  • Patients who have gastrointestinal bleeding or peptic ulcer (except scar) within 30 days
  • History of a gastroesophageal surgery such as antigastric-secretion surgery or esophagogastrectomy (except a simple perforator surgery)
  • Patients who have severe disability in GI, Kidney, Liver and Blood
  • Pregnant women, Lactating women and Women of child-bering potential who are not using adequate means of
  • History of allergy to COX-2 inhibitors or sulphonamides or other NSAIDs
  • Any condition that, in the view of the investigator, would interfere with study participation
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
119 participants (actual)

Study arms

  • Experimental
    CELBESTA® and CELEBREX® placebo

    CELBESTA® and CELEBREX® placebo is administered twice daily for 6 weeks

    Drug: CELBESTA® · Drug: CELEBREX® placebo

  • Active comparator
    CELEBREX®

    CELEBREX® and CELBESTA® placebo is administered twice daily for 6 weeks

    Drug: CELEBREX® · Drug: CELBESTA® placebo

Interventions

  • 1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks

    Also known as: celecoxib

  • 1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks

    Also known as: celecoxib

  • DrugCELEBREX® placebo

    1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks

    Also known as: celecoxib placebo

  • DrugCELBESTA® placebo

    1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks

    Also known as: celecoxib placebo

06

What researchers measure

Primary outcomes

  1. Change from baseline of 100mm VAS about pain in study at week 6

    Time frame: week 6

Secondary outcomes

  1. Change from baseline of DAS28-ESR(Disease Activity Score in 28 joints) at week 6

    Time frame: week 6

07

Study locations

1 site
  • Kyung Hee University Hospital
    Seoul, 130-702, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2015 to primary completion in Dec 2017, 25 months.

Of 25 industry-sponsored phase 4 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 26 months of starting (the median); a quarter within 16 and three quarters within 44. This study's 25 months is close to that.

Counting every sponsor, half of 104 studies reached it within 42 months; a quarter within 25 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2016
First posted
May 23, 2016
StartActual
Nov 2, 2015
Primary completionActual
Dec 26, 2017
CompletionActual
Dec 26, 2017
Last update
Feb 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02780323
Responsible party
Sponsor
First posted
May 23, 2016
Start date
Nov 2, 2015
Primary completion
Dec 26, 2017
Completion
Dec 26, 2017
Last update
Feb 5, 2020

Study contacts

Seung-jae Hong, MD,PhD
principal investigator · Kyung Hee University Hospital
Sungsoo Kim, MD,PhD
principal investigator · Gangneung Asan Hospital
Sangil Lee, MD,PhD
principal investigator · Gyeongsang National Hospital
Changnam Son, MD,PhD
principal investigator · Keimyung University Dongsan Medical Center
Yeong Ho Seo, MD,PhD
principal investigator · Korea University
Geun-Tae Kim, MD,PhD
principal investigator · Kosin University Gospel Hospital
Jin-Wuk Hur, MD,PhD
principal investigator · Seoul Eulji Hospital
Hyun-Sook Kim, MD,PhD
principal investigator · Soonchunhyang University Hospital
Myeong Soo Lee, MD,PhD
principal investigator · Wonkwang University Hospital
Yun Sung Kim, MD,PhD
principal investigator · Chosun University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Celecoxib

Start the discussion